On the basis of the bioinformatics analysis and experimental results, we believed that the TGF-β-MYC-ADAMTS2 axis might be a potential therapeutic target for cardiac hypertrophy and HF. The gene discussed is TGFB1; the disease is cardiac hypertrophy.